Intervention not reported
CRFWVT (Rezūm) (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
TIND (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
studies 1469 participants · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
Intervention not reported
PUL (UroLift) (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Hospitalisation for RSV infection · children (0 to 24 months)
Palivizumab leads to lower hospitalisation due to RSV infection compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
All‐cause mortality · children (0 to 24 months)
Palivizumab showed no clear difference in mortality compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Adverse events · children (0 to 24 months)
Palivizumab showed no clear difference in adverse events compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Hospitalisation due to respiratory‐related illness · children (0 to 24 months)
Palivizumab probably leads to lower hospitalisation due to respiratory‐related illness compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
RSV infection · children (0 to 24 months)
Palivizumab may leads to lower RSV infection compared with placebo, no intervention or standard care (low certainty).
1 finding from 1 review
Number of wheezing days · children (0 to 24 months)
Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · people with dementia
1 finding from 1 review
Behavioural and psychological symptoms · people with dementia
1 finding from 1 review
Adverse effects · people with dementia
1 finding from 1 review
Quality of life · people with dementia
1 finding from 1 review
Mood · people with dementia
1 finding from 1 review
Sleep · people with dementia
1 finding from 1 review
Activities of daily living · people with dementia
1 finding from 1 review
Quitline referral vs control · smoking cessation in hospitalised patients
It is very uncertain whether telephone quitline referral changes quitline referral vs control compared with no treatment or usual care (very low certainty).
1 finding from 1 review